Ray Dalio's HALO Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 561,577 shares of Halozyme Therapeutics, Inc. (HALO) worth $37.79 M, representing 0.14% of the portfolio. First purchased in 2023-Q2, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in HALO, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 487,081 shares. Largest reduction occurred in Q3 2023, reducing 54,533 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +74,496 | Add 15.29% | 561,577 | $67.30 |
| Q3 2025 | +487,081 | New Buy | 487,081 | $73.34 |
| Q4 2024 | -11,515 | Sold Out | 0 | $0.00 |
| Q3 2024 | -21,706 | Reduce 65.34% | 11,515 | $57.24 |
| Q2 2024 | +26,159 | Add 370.42% | 33,221 | $52.36 |
| Q3 2023 | -54,533 | Reduce 88.53% | 7,062 | $38.20 |
| Q2 2023 | +61,595 | New Buy | 61,595 | $36.07 |
Ray Dalio's Halozyme Therapeutics Investment FAQs
Ray Dalio first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2023, acquiring 61,595 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Halozyme Therapeutics, Inc. (HALO) for 9 quarters since Q2 2023.
Ray Dalio's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q3 2025, adding 487,081 shares worth $35.72 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 561,577 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $37.79 M.
As of the Q4 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.14% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Halozyme Therapeutics, Inc. (HALO) was 561,577 shares, as reported at the end of Q4 2025.